Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia

Medical Oncology

Volumn 19, Issue 2, 2002, Pages 79-86

  Mackenzie, Karen L ^a,c   Franco, Sonia ^a   Naiyer, Afzal J ^b   May, Chad ^a   Sadelain, Michel ^a   Rafii, Shahin ^b   Moore, Malcolm A S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

Adverse events; Anemia; Blood transfusions; Myeloproliferative disorders; Myeofibrosis; Spleen; Thalidomide

Indexed keywords

LEPROSTATIC AGENT; THALIDOMIDE; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PHASE 2 CLINICAL TRIAL; SPLEEN; TREATMENT FAILURE; CLINICAL ARTICLE; CONSTIPATION; DOSE RESPONSE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; HEMOGLOBIN DETERMINATION; LUNG HEMORRHAGE; NEUROPATHY; PARESTHESIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; VERTIGO; XEROSTOMIA;

ADULT; AGED; ANEMIA; BLOOD TRANSFUSION; BONE MARROW; FEMALE; HUMANS; LEPROSTATIC AGENTS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; SPLEEN; THALIDOMIDE; TREATMENT FAILURE; HUMAN; MIDDLE AGE;

EID: 0036017505     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:19:2:79     Document Type: Article

References (17)

1. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia
2. Characteristics of bone marrow fibroblast colony-forming cells and their progeny in patients with myeloproliferative disorders
3. Reversal of myelofibrosis with hydroxyurea
4. Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines
5. Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascular density
6. Lite expectancy of patients with chronic nonleukemic myeloproliferative disorders
7. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmstead county study, 1976-1995
8. Thalidomide is an inhibitor of angiogenesis
9. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
10. Antitumor activity of thalidomide in refractory multiple myeloma
11. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
12. Thalidomide produces transfusion independence in patients with long-standing refractory anemias of patients with myelodysplastic syndromes
13. Thalidomide anti-angiogenesis therapy in Philadelphia-negative myeloproliferative disorders and myelofibrosis
14. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
15. Thalidomide treatment in myelofibrosis with myeloid metaplasia
16. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia
17. Thalidomide in agnogenic and secondary myelofibrosis